Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.

The aim oh this study is to determine the safety and recommended dose of trifluridine/tipiracil plus capecitabine and bevacizumab combination (part 1, dose escalation phase) and to assess its activity in previously untreated mCRC patients who are deemed not eligible for intensive chemotherapy (part 2, expansion phase).

本研究旨在明确曲氟尿苷替匹嘧啶（trifluridine/tipiracil）联合卡培他滨（capecitabine）与贝伐珠单抗（bevacizumab）联合方案的安全性与推荐剂量（第1部分：剂量递增阶段），并评估该方案在既往未接受治疗且被认为不适合强化化疗的转移性结直肠癌（metastatic colorectal cancer, mCRC）患者中的抗肿瘤活性（第2部分：扩展阶段）。